▲点击图片扫描二维码报名 秋风送爽，丹桂飘香，科学的原野再度迎来丰收的序曲。我们谨以最诚挚的热情，邀您共赴上海张江，参加一场属 于生物药早期研发领域的科学盛宴 —— 第四届蛋白质科学及抗体发现研讨会 。 自 2021 年扬帆起航，四载春 秋，我们步履不停，足迹遍布上海、苏州、成都等创新热土，汇聚了数千名科学同仁，共同谱写了生物医药研发的 壮丽诗篇。 强强联袂，科学为舵，共启腾飞新程 秉持 " 聚焦 蛋白创新，加速行业 腾飞 " 的永恒主题，我们始终以 " 专业性铸就根基，学术性拓深维度 " 为灵 魂，致力于打造一个与国际前沿比肩的顶级交流平台。本届盛会将于 2025 年 11 月 21 日（星期五） ，在充满活 力的 上海张江举行。让我们暂别日常的喧嚣，回归学术的本真，于思维的碰撞中，探寻技术突破的星辰大海。 承科学之脉，启创新之局 秉承 " 严肃定位，严格准入，严谨科学（数据） " 的 三严原则 ， 我们 致力于为 科研人员 打造一个聚焦早期研 发、强调技术落地、重视数据交流的高质量平台。 本届大会在延续往届专业性与前瞻性的基础上，进一步聚焦早期研发与技术突破，设置主论坛和 自免和肿瘤药物 开发、复杂抗体与 ...

Group 1: Stock Market Activity - 27 stocks were listed on the institutional trading leaderboard today, with 17 stocks experiencing net buying and 10 stocks facing net selling [1] - The top three stocks with the highest net buying by institutions were: Xiaocheng Technology (¥203 million), Hainengda (¥107 million), and Liao Co., Ltd. (¥64.38 million) [1][2] - Xiaocheng Technology saw a price increase of 19.98%, with 4 buyers and 3 sellers [2] Group 2: Gold Market Insights - Goldman Sachs believes the current rise in gold prices has structural support and is unlikely to face selling risks in the short term, with a year-end target price of $3,700 per ounce [3] - Shenwan Hongyuan indicates that the trend of de-globalization is reshaping the global credit landscape, with central bank gold purchases leading gold prices, and current central bank gold reserves remaining low [3] Group 3: AI and Technology Developments - Hengfeng Information integrates community cameras and IoT sensors through MCP Server, allowing AI agents to automatically identify key personnel and facility damages [4] - ByteDance's new AI collaborative office platform "Coze Space" aims to enhance user efficiency by providing comprehensive services from answering to problem-solving [4] - The MCP extension integration allows agents to access various external tools and services, enriching their functionality and enabling them to perform more complex tasks [5] Group 4: Pharmaceutical Sector - Shutaishen is recognized as a leading domestic small nucleic acid drug developer [6] - Kexing Pharmaceutical has established a complete biopharmaceutical R&D innovation system, with multiple leading technology platforms including prokaryotic and eukaryotic cell systems [6]